Understanding COVID‐19 Risk in Patients With Immune‐Mediated Inflammatory Diseases: A Population‐Based Analysis of SARS–CoV‐2 Testing
Open Access
- 27 September 2022
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 75 (2) , 317-325
Abstract
Objective: To investigate the incidence of and factors associated with SARS–CoV‐2 testing and infection in immune‐mediated inflammatory disease (IMID) patients versus matched non‐IMID comparators from the general population.Methods: We conducted a population‐based, matched cohort study among adult residents from Ontario, Canada, from January 2020 to December 2020. We created cohorts for the following IMIDs: rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, ankylosing spondylitis, systemic autoimmune rheumatic diseases, multiple sclerosis (MS), iritis, inflammatory bowel disease (IBD), polymyalgia rheumatica, and vasculitis. Each patient was matched with 5 patients without IMIDs based on sociodemographic factors. We estimated the incidence of SARS–CoV‐2 testing and infection in IMID patients and non‐IMID patients. Multivariable logistic regressions assessed odds of SARS–CoV‐2 infection.Results: We studied 493,499 patients with IMIDs and 2,466,946 patients without IMIDs. Patients with IMIDs were more likely to have at least 1 SARS–CoV‐2 test versus patients without IMIDs (27.4% versus 22.7%), but the proportion testing positive for SARS–CoV‐2 was identical (0.9% in both groups). Overall, IMID patients had 20% higher odds of being tested for SARS–CoV‐2 (odds ratio 1.20 [95% confidence interval 1.19–1.21]). The odds of SARS–CoV‐2 infection varied across IMID groups but was not significantly elevated for most IMID groups compared with non‐IMID comparators. The odds of SARS–CoV‐2 infection was lower in IBD and MS and marginally higher in RA and iritis.Conclusion: Patients across all IMIDs were more likely to be tested for SARS–CoV‐2 versus those without IMIDs. The risk of SARS–CoV‐2 infection varied across disease subgroups.Keywords
Funding Information
- Arthritis Society (Stars Career Development Award (STAR‐19‐0610))
- Canadian Institutes of Health Research (New Investigator Award)
- McGill University (James McGill Professor of Medicine Award)
This publication has 33 references indexed in Scilit:
- High-risk human papilloma virus infection and cervical neoplasm in female inflammatory bowel disease patients: a cross-sectional studyGastroenterology Report, 2019
- Infection in systemic lupus erythematosus, similarities, and differences with lupus flareThe Korean Journal of Internal Medicine, 2017
- Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case–control study in AsiaBMJ Open, 2017
- Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, CanadaMultiple Sclerosis Journal, 2014
- Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, CanadaJournal of Clinical Epidemiology, 2014
- Accuracy of Canadian Health Administrative Databases in Identifying Patients With Rheumatoid Arthritis: A Validation Study Using the Medical Records of RheumatologistsArthritis Care & Research, 2013
- Population Based Study of 12 Autoimmune Diseases in Sardinia, Italy: Prevalence and ComorbidityPLOS ONE, 2012
- The prevalence of 30 ICD-10 autoimmune diseases in DenmarkImmunologic Research, 2010
- Autoimmune Diseases Co-occurring Within Individuals and Within FamiliesEpidemiology, 2006
- Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confoundingBMJ, 2005